4th Mar 2025 12:00
TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Director/PDMR Shareholding
Alderley Park, UK - 4 March 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry has been notified that Dr Helen Kuhlman, Chief Business Officer has purchased 1,500,000 Ordinary Shares of 0.25 pence each ("Ordinary Shares") at a price of 0.24 pence per Ordinary Share.
The notifiable interest of Dr Helen Kuhlman is now 2,555,744 Ordinary Shares, representing 0.5% of the issued Ordinary Share capital of the Company.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a. | Name | Dr Helen Kuhlman | ||||
2 | Reason for notification | |||||
a. | Position/Status | Chief Business Officer (PDMR) | ||||
b. | Initial notification/ Amendment | Initial | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a. | Name | TheraCryf plc | ||||
b. | LEI | 213800NO3E6TSTQO8K20 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a. | Description of the financial instrument, type of instrumentIdentification Code |
Ordinary Shares of 0.25p each
GB00BSVYN304 | ||||
b. | Nature of the transaction | Purchase of Ordinary Shares | ||||
c. | Price(s) and volume(s) |
| ||||
d. | Aggregated information - Aggregated Volume - Price |
As above | ||||
e. | Date of the transaction |
| ||||
f. | Place of the transaction | XLON
| ||||
Enquiries
|
About TheraCryf plc
TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy [*orphan indication].
The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).
TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.
For further information, please visit: www.theracryf.com.
Related Shares:
Theracryf PLC